Multimodal treatments combined with gamma knife surgery for primary atypical teratoid/rhabdoid tumor of the central nervous system: a single-institute experience of 18 patients

Childs Nerv Syst. 2018 Apr;34(4):627-638. doi: 10.1007/s00381-017-3688-3. Epub 2017 Dec 7.

Abstract

Objectives: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare, highly malignant tumor of the central nervous system with poor prognosis. Nowadays, multimodal management, including surgery, chemotherapy (CMT), and radiation therapy (RT), is advocated. However, AT/RT treatment with gamma knife surgery (GKS) was rarely reported. The aim of this study was to assess the efficacy and safety of GKS for the treatment of AT/RT.

Patients and methods: Medical records of AT/RT patients who underwent surgery from 2007 to 2014 at the West China Hospital were retrospectively reviewed and statistically analyzed.

Results: Eighteen patients (12 males and 6 females) were presented with AT/RTs. Median age during presentation was 20.5 months (range, 4-179 months). Twelve patients were < 3 years and six patients were > 3 years. Tumor location was supratentorial in seven patients, infratentorial in ten patients, and center area of the brain in one patient. Treatments performed were as follows: surgery alone in two patients, surgery+RT in two patients, surgery+CMT in five patients, surgery+CMT+RT in two patients, and surgery+CMT+RT+GKS in seven patients. The 2-year overall survival (OS) rate and event-free survival (EFS) rate for all 18 consecutive patients were 33.3 and 27.8%, respectively. Cox regression analyses showed that multimodal management combined with GKS was an independent positive prognostic factor for OS.

Conclusions: Although AT/RTs are lethal cancer types, the OS of the disease was improved by using multimodal therapeutic strategies, including surgery, CMT, and RT, combined with GKS.

Keywords: Atypical teratoid/rhabdoid tumors; Chemotherapy; Gamma knife surgery; INI1; Prognosis; Radiation therapy.

MeSH terms

  • Adolescent
  • Antineoplastic Agents / therapeutic use*
  • Central Nervous System Neoplasms / therapy*
  • Child
  • Child, Preschool
  • Combined Modality Therapy*
  • Female
  • Humans
  • Infant
  • Keratins / metabolism
  • Male
  • Mucin-1 / metabolism
  • Nerve Tissue Proteins / metabolism
  • Radiosurgery / methods*
  • Retrospective Studies
  • Rhabdoid Tumor / therapy*
  • Treatment Outcome
  • Vimentin / metabolism

Substances

  • Antineoplastic Agents
  • Mucin-1
  • Nerve Tissue Proteins
  • Vimentin
  • Keratins